Representative Recent Publications (out of > 350 total; H index – 143)
Peer reviewed articles
Tsuchida T, A. Lee YA, Fujiwara N, Ybanez M, Allen B, Martins S, Fiel MI, Goossens N, Chou, H, Hoshida Y, Friedman SL. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. Journal of Hepatology, 69(2):385-395, 2018.
Labgaa I, Villacorta-Martin C, D’Avola D, Craig A, von Felden J, Martins-Filho SN, Daniela Sia D, Stueck A, Ward SC, Fiel MI, Mahajan M, Tabrizian P, Thung SN, Ang C, Friedman SL, Llovet JM, Schwartz M, Villanueva A. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene, 37(27):3740-3752, 2018.
Lee YA, Noon LA, Akat KM, Ybanez MD, Lee T-F, Berres M-L, Fujiwara N, Goossens N, Chou H, Parvin-Nejad F, Khambu B, Kramer EGM, Gordon R, Pfleger C, Germain D, John GR, Campbell KN, Yue Z, Yin X-M, Cuervo AM, Czaja MJ, Fiel MI, Hoshida Y, and Friedman SL. .Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nature Communications, 9(1):4962, 2018.
Amor C, Feucht J, Leibold J, Ho Y-J, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Xing Li X, Giavridis T, Kulick A, Houlihan S, Peerschke E, Friedman SL, Ponomarev V, Piersigilli A, Sadelain M, Lowe SW. Senolytic CAR T cells reverse senescence-associated pathologies. Nature, 583: 127-132, 2020.
Urushima H, Yuasa H, Matsubara T, Kuroda N, Hara Y, Inoue K, Wake K, Sato T, Friedman SL, Ikeda K. Activation of hepatic stellate cells requires dissociation of E-cadherin-containing adherens junctions with hepatocytes. American Journal of Pathology, S0002-9440(20)30562-9, 2020.
Carter JK, Bhattacharya D, Borgerding JN, Fiel MI, Faith JJ, Friedman SL. Modeling dysbiosis of human NASH in mice: Loss of gut microbiome diversity and overgrowth of Erysipelotrichales. PLoS One, 16(1): e0244763, 2021.
Bhattacharya D, Basta B, Mato, JM Craig A, Fernández-Ramos D, Lopitz-Otsoa F, Tsvirkun D, Hayardeny L, Chandar V, Schwartz RE, Villanueva A and Friedman SL. Aramchol downregulates stearoyl CoA-Desaturase 1 (SCD 1) in hepatic stellate cells to attenuate cellular fibrogenesis. J HEP Reports, in press, 2021.
Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Moeini A, Peix J, Oliveira CP, Alves VA, Boffeta P, Lachenmayer A, Roessler S, Minguez M, Schirmacher P, Dufour J-F, Thung S, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwälder M, Sanyal A, Friedman SL, Sia D, Llovet JM. Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatology, in press, 2021.
Bhattacharya D, Becker C, Readhead B, Goossens N, Novik J, Fiel MI, Cousens LP, Magnusson B, Backmark A, Hicks R, Dudley JT and Friedman SL. Repositioning of a Novel GABA-B receptor Agonist, AZD3355 (Lesogaberan), for the Treatment of Non-Alcoholic Steatohepatitis. Submitted, 2021.
Review articles
Friedman SL, Neuschwander-Tetri BA, Rinella M and Arun J. Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine, 4(7):908-922, 2018.
Lemoinne S and Friedman SL. New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases. Current Opinion in Pharmacology, 49:60-70, 2019.
Wang S and Friedman SL. Taming the savage breast from within – Tcf21, a novel regulator of stellate cell deactivation (invited editorial). Hepatology, 71(4):1150-1153, 2020.
Crismale JF, Friedman SL. Acute liver injury and decompensated cirrhosis. Med Clin North Am. 104(4):647-662, 2020.
Young S, Tariq R, Provenza J, Satapathy, SK, Faisal K, Choudhury A, Friedman SL, Singal AK. Prevalence and profile of fatty liver disease in lean adults: a systematic review and meta-analysis. Hepatology Communications, 4 (7):953 – 972, 2020.
Asgharpour A, Dinani A, Friedman SL. Basic science to clinical trials in NAFLD & ALD: collaboration with industry. Translational Gastroenterology and Hepatology, 6:5, 2021.
Trivedi P, Wang S and Friedman SL. The power of plasticity – metabolic regulation of hepatic stellate cells. Cell Metabolism, S1550-4131(20)30595-7, 2021.
Rockey DC and Friedman SL. Fibrosis regression after eradication of hepatitis C virus – from bench to bedside. Gastroenterology, in press, 2021.
Huisman TM, Dieterich DT, Friedman SL. Experimental and investigational targeted therapies for the management of fibrosis in NASH: an update. J Experimental Pharmacology, in press, 2021.
Shulman G*, Friedman SL*, Loomba R*. Mechanisms and disease consequences of nonalcoholic fatty liver disease, Cell, in press, 2021. (* shared equal authorship).
